Von Willebrand Disease: Bridging the Evidence Gap with a Call to Action for Equitable Care
Nathan Connell, Hematologist at Harvard Medical School, shared a post on LinkedIn:
“Thank you to Drs. Kelsey Uminski, Paula James, and Roy Khalife for asking me to join them in preparing this commentary in Haemophilia Journal, “Bridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence-Based Care.”
For decades, von Willebrand disease (VWD), the most common inherited bleeding disorder, has been under-researched compared to hemophilia. This evidence gap has led to significant challenges in patient care, including clinical uncertainties and wide variability in practice. This paper outlines why this gap exists and presents a coordinated, five-point research agenda to help close it:
▪️Patient-Centered Trial Design: Shifting away from endpoints that don’t capture the full impact of VWD and focusing on what matters most to patients, like the effect on quality of life.
▪️Adoption of Core Outcome Sets: Standardizing key outcomes to make research more comparable and clinically applicable.
▪️PK-Guided Therapy: Developing accessible tools for individualized, precise dosing, similar to what has revolutionized hemophilia care.
▪️Network Research and Real-World Data: Expanding registries and networks to gather data and better understand long-term outcomes for patients.
▪️Embedded Patient and Clinician Partnerships: Meaningfully engaging with patients and providers to ensure research questions are relevant to real-world needs.
This call to action is about more than just science; it’s about equity. VWD has suffered from historical underinvestment and under recognition, especially for conditions that disproportionately affect women. We believe equitable care requires equitable evidence, and VWD is too important to overlook.
Read the full commentary here.”
More posts featured in Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry